Page last updated: 2024-09-27

menogaril

Description

Menogaril: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID320697
SCHEMBL ID1651790
MeSH IDM0026248

Synonyms (10)

Synonym
71628-96-1
menogaril
dimethylamino-pentahydroxy-methoxy-dimethyl-[?]dione
2,6-epoxy-2h-naphthaceno[1,2-b]oxocin-9,16-dione, 4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-, (2r,3s,4r,5r,6r,11r,13r)-
NSC269148 ,
7-o-methylnogarol
SCHEMBL1651790
7-0-methylnogarol
LWYJUZBXGAFFLP-FEMZJCMLSA-N
(10s,12r,22s,23r,24r)-23-(dimethylamino)-4,8,12,22,24-pentahydroxy-10-methoxy-1,12-dimethyl-20,25-dioxahexacyclo[19.3.1.02,19.05,18.07,16.09,14]pentacosa-2,4,7(16),8,14,18-hexaene-6,17-dione

Research Excerpts

Overview

ExcerptReference
"Menogaril is a semisynthetic anthracycline with relative lack of cardiotoxicity. "( Benson, AB; Blough, R; Kilton, L; Kucuk, O; Wade, JL, 2000)
"Menogaril is a semisynthetic anthracycline that is less cardiotoxic than doxorubicin in a preclinical model. "( Carbone, P; Citrin, DL; Hudes, GR; Khandekar, JD; Manola, J; Obasaju, C; Trump, DL, 2001)
"Menogaril is a new semisynthetic anthracycline agent derived from the antitumor antibiotic Nogalomycin. "( Hudis, CA; Kelsen, DP, 1992)
"Menogaril (TUT-7) is a novel antitumor antibiotic belonging to anthracyclines. "( Akimoto, T; Aso, R; Hara, H; Nakama, K; Ohashi, K; Takahashi, F, 1992)
"Menogaril is an anthracycline presently in Phase II clinical trials. "( Badiner, GJ; Bhuyan, BK; Groppi, VE; Moy, BC; Smith, KS; Tarpley, WG, 1990)
"Menogaril is an antitumor agent of the anthracycline type which is less cardiotoxic than doxorubicin in a chronic rabbit model and is active in experimental tumor systems when given by p.o. "( Adams, WJ; Brewer, JE; Dalm, EA; Hosley, JD; McGovren, JP, 1989)
"Menogaril is a new anthracycline analog of nogalamycin. "( Long, HJ; Moertel, CG; Powis, G; Schutt, AJ, 1987)
"Menogaril is an active drug used in the treatment of patients with advanced breast cancer who have not had prior systemic therapy."( Cavalli, F; Gundersen, S; Renard, J; Sessa, C; ten Bokkel Huinink, W, 1988)

Actions

ExcerptReference
"Menogaril displays little activity in patients with previously treated MM."( Brodkin, RA; Brown, RC; Case, LD; Cruz, JM; Dalton, HB; Jackson, DV; Muss, HB; Ramseur, WL; Richards, F; Zekan, PJ, 1992)

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-199042 (42.42)18.7374
1990's50 (50.51)18.2507
2000's2 (2.02)29.6817
2010's1 (1.01)24.3611
2020's4 (4.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (33.33%)5.53%
Reviews11 (10.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other61 (56.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Safety/Toxicity (2)

ArticleYear
Comparative genotoxicity of adriamycin and menogarol, two anthracycline antitumor agents.
Cancer research, Volume: 43, Issue: 11
1983
Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Biochemical and biophysical research communications, Sep-16, Volume: 131, Issue: 2
1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (10)

ArticleYear
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Investigational new drugs, Volume: 11, Issue: 1
1993
Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia.
Investigational new drugs, Volume: 11, Issue: 4
1993
Pharmacokinetics and acute cardiovascular effects of menogaril in patients with metastatic tumors.
International journal of clinical pharmacology and therapeutics, Volume: 33, Issue: 2
1995
Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
European journal of cancer & clinical oncology, Volume: 24, Issue: 6
1988
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Cancer research, Nov-15, Volume: 47, Issue: 22
1987
Pharmacokinetics of 7-con-O-methylnogarol in patients with solid tumors.
Cancer chemotherapy and pharmacology, Volume: 20, Issue: 1
1987
Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Cancer treatment reports, Volume: 71, Issue: 6
1987
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Cancer research, Volume: 46, Issue: 3
1986
Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Cancer research, Nov-15, Volume: 49, Issue: 22
1989
[Pharmacokinetic studies of menogaril (TUT-7) with rats].
Gan to kagaku ryoho. Cancer & chemotherapy, Volume: 19, Issue: 11
1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (5)

ArticleYear
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Investigational new drugs, Volume: 11, Issue: 1
1993
Potential role of oral anthracyclines in older patients with cancer.
Drugs & aging, Volume: 4, Issue: 5
1994
Menogaril: a new anthracycline agent entering clinical trials.
Investigational new drugs, Volume: 2, Issue: 4
1984
Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
European journal of cancer & clinical oncology, Volume: 24, Issue: 6
1988
Pharmacokinetics and systemic bioavailability of menogaril, an anthracycline antitumor agent, in the mouse, dog, and monkey.
Cancer research, Nov-15, Volume: 49, Issue: 22
1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (11)

ArticleYear
[TUT-7 phase I clinical study. TUT-7 Study Group].
Gan to kagaku ryoho. Cancer & chemotherapy, Volume: 24, Issue: 9
1997
A phase I clinical and pharmacokinetic study of the oral and the oral/intravenous administration of menogaril.
Investigational new drugs, Volume: 11, Issue: 1
1993
Potential role of oral anthracyclines in older patients with cancer.
Drugs & aging, Volume: 4, Issue: 5
1994
Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas.
American journal of clinical oncology, Volume: 11, Issue: 2
1988
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Cancer research, Nov-15, Volume: 47, Issue: 22
1987
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Cancer research, Volume: 46, Issue: 3
1986
Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Cancer research, Volume: 45, Issue: 11 Pt 1
1985
Phase II evaluation of menogaril (NSC-269148) in non-small cell lung carcinoma. A Southwest Oncology Group study.
Investigational new drugs, Volume: 9, Issue: 1
1991
Phase II evaluation of menogaril in patients with advanced cervical carcinoma. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic.
Investigational new drugs, Volume: 9, Issue: 4
1991
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.
Annals of oncology : official journal of the European Society for Medical Oncology, Volume: 3, Issue: 3
1992
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Interactions (1)

ArticleYear
Synergistic combination of menogarol and melphalan and other two drug combinations.
Investigational new drugs, Volume: 3, Issue: 3
1985
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]